GRAIL (GRAL) Expected to Announce Quarterly Earnings on Wednesday

GRAIL (NASDAQ:GRAL) is expected to release its Q3 2026 results after the market closes on Wednesday, November 4th. Analysts expect GRAIL to announce earnings of ($2.45) per share and revenue of $44.21 million for the quarter. Individuals can find conference call details on the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 4:30 PM ET.

GRAIL (NASDAQ:GRAL) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($2.56) EPS for the quarter, beating analysts’ consensus estimates of ($2.66) by $0.10. GRAIL had a negative net margin of 236.95% and a negative return on equity of 15.88%. The business had revenue of $44.69 million for the quarter, compared to analysts’ expectations of $42.39 million. On average, analysts expect GRAIL to post ($10.07) EPS for the current fiscal year and ($10.80) EPS for the next fiscal year.

GRAIL Price Performance

Shares of GRAIL stock traded up $6.63 on Tuesday, hitting $140.39. 210,661 shares of the company’s stock traded hands, compared to its average volume of 970,116. The company has a market capitalization of $6.27 billion, a price-to-earnings ratio of -14.42 and a beta of 2.83. GRAIL has a one year low of $41.50 and a one year high of $166.48. The company has a fifty day moving average of $113.10 and a two-hundred day moving average of $78.71.

Insider Transactions at GRAIL

In related news, insider Andrew Partridge sold 7,873 shares of the business’s stock in a transaction on Monday, October 5th. The stock was sold at an average price of $146.39, for a total transaction of $1,152,528.47. Following the sale, the insider directly owned 155,865 shares in the company, valued at approximately $22,817,077.35. The trade was a 4.81% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Joshua J. Ofman sold 61,452 shares of the stock in a transaction dated Monday, September 21st. The stock was sold at an average price of $97.74, for a total value of $6,006,318.48. Following the sale, the chief executive officer directly owned 362,271 shares in the company, valued at $35,408,367.54. This trade represents a 14.50% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 129,944 shares of company stock valued at $14,832,805 over the last three months. Company insiders own 1.83% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have commented on GRAL. Royal Bank Of Canada initiated coverage on shares of GRAIL in a report on Thursday, September 17th. They issued a “sector perform” rating and a $84.00 price target for the company. TD Cowen lifted their price objective on shares of GRAIL from $88.00 to $180.00 and gave the stock a “buy” rating in a report on Tuesday, October 13th. Robert W. Baird lifted their price objective on shares of GRAIL from $96.00 to $118.00 and gave the stock an “outperform” rating in a research report on Tuesday, September 22nd. Wall Street Zen raised GRAIL from a “sell” rating to a “hold” rating in a report on Sunday, September 13th. Finally, UBS Group increased their target price on shares of GRAIL from $105.00 to $175.00 and gave the stock a “buy” rating in a research report on Friday, October 2nd. Five equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $119.80.

GRAIL Company Profile

GRAIL, Inc (NASDAQ: GRAL) is a healthcare company focused on developing blood-based screening technologies for the early detection of cancer. Its principal product is Galleri, a multi-cancer early detection test designed to identify DNA patterns associated with multiple types of cancer from a single blood sample.

Galleri is intended for use alongside recommended cancer screenings and is available by prescription through qualified healthcare providers in the United States. The test is offered as a laboratory-developed test and has not been approved or cleared by the U.S.